

Special Issue

Mechanisms Leading to Neurodegeneration in the ALS and FTD Spectrum

Message from the Guest Editors

Amyotrophic lateral sclerosis (ALS) is the third most common neurodegenerative disorder, and frontotemporal dementia (FTD) is the fourth most common neurodegenerative disorder. Both diseases share common molecular mechanisms and are now considered to be part of the same disease spectrum ("ALS-FTD spectrum"). Most ALS and FTD patients are sporadic of unknown cause, whereas mendelian mutation can be found in 10–15% of them. The exact molecular paths leading to neurodegeneration in these diseases is not well known, albeit several mechanisms have been shown to be involved. As a consequence, no effective treatments have been found to date. This Special Issue of *Biomedicines* aims to cover the mechanisms of neurodegeneration occurring in ALS and FTD from different perspectives, including but not limited to:

- Genetics and epigenetics;
- Neuroinflammation;
- Protein aggregation;
- Mitochondrial damage;
- Excitotoxicity;
- Novel mechanisms;
- Neurodegeneration biomarkers;
- Disease spread mechanisms;
- Therapeutical approaches to arrest neurodegeneration.

Guest Editors

Dr. Juan Francisco Vázquez-Costa

Hospital Universitari i Politècnic La Fe, Valencia, Spain

Dr. Laura Moreno-Martínez

LAGENBIO, University of Zaragoza, Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), Aragon Institute for Health Research (IIS Aragon), Calle Miguel Servet 13, 50013 Zaragoza, Spain

Deadline for manuscript submissions

closed (15 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/127959

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).